SCHEMBL23564656

SCHEMBL23564656

COc1ccc(C(C)C(=O)c2ccc(O)cc2OC)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 10/20 0.67
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
CYP3A4 P08684 2/20 0.57
MAPT P10636 2/20 0.57
PPARG P37231 1/20 0.57
CAPN1 P07384 1/20 0.45
PARP1 P09874 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523355 0.86 HIF1A (0.79) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL30511127 0.86 HIF1A (0.79) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL23564661 0.86 HIF1A (0.79) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL23523596 0.82 HIF1A (0.62) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL30511137 0.82 HIF1A (0.62) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL23523591 0.80 HIF1A (1.00) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL23564659 0.80 HIF1A (1.00) HIF1AKMT2AMEN1CYP3A4MAPT
SCHEMBL23523652 0.78 HIF1A (1.00) HIF1AKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL30511133 0.78 HIF1A (1.00) HIF1AKMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL23523608 0.77 HIF1A (1.00) HIF1AKMT2AMEN1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188753-A1 NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KP) 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188753-A1 NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT HIF1AN, HIF1A, HYOU1 HIF1A 2/4885KMT2A 1179/4885MEN1 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.